Last reviewed · How we verify
NCT05724550
Diaphragm Function After Reversal of Rocuronium-induced Neuromuscular Blockade With Sugammadex or Neostigmine in Children
NA trial testing Sugammadex in Neuromuscular Block, Residual in 73 participants. Completed in 8 June 2024.
7 June 2024
Quick facts
| Lead sponsor | Seoul National University Hospital |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | prevention |
| Enrollment | 73 |
| Start date | 22 February 2023 |
| Primary completion | 7 June 2024 |
| Estimated completion | 8 June 2024 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
- Sugammadex — full drug profile →
- Neostigmine (NEOSTIGMINE) — full drug profile →
Conditions studied
- Neuromuscular Block, Residual — all drugs for Neuromuscular Block, Residual →
Sponsor
Seoul National University Hospital
Who can join
Adults 2 to 7, any sex, with Neuromuscular Block, Residual. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is to evaluate the recovery of diaphragm function and atelectasis after reversal of neuromuscular blockade with Neostigmine and Sugammadex using lung ultrasound and diaphragm ultrasound for children aged 2 to 7 who are scheduled for the surgical procedure under general anesthesia.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Ultrasonographic assessment of sugammadex-enhanced early recovery of diaphragmatic function in children: A randomised double-blind controlled trial.
Park JB, Kim TW, Ji SH, Jang YE, et al · · 2025 · cited 3× · PMID 40625141 · DOI 10.1097/eja.0000000000002231
Verify or expand the search:
- PubMed search for NCT05724550
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Sugammadex
Trials testing the same drug.
- NCT07477132 — A Dose-response Study to Determine the Right Dosage of Sugammadex as a Reversal Agent of Rocuronium in Infants Between 1 · Phase 4 · not yet recruiting
- NCT07271875 — Neuromuscular Blocking Agents on Gastrointestinal Function Following Colorectal Surgery · Phase 3 · not yet recruiting
- NCT07309393 — Impact of Sugammadex Versus Neostigmine on Early Postoperative Pulmonary Function · NA · recruiting
- NCT07203287 — Risk of Acute Complications With Rocuronium vs Cisatracurium in Patients With Chronic Kidney Disease · Phase 4 · recruiting
- NCT06575036 — Sugammadex Dose Finding Under Two Years Old · Phase 2 · not yet recruiting
Other recruiting trials for Neuromuscular Block, Residual
Currently open trials in the same condition.
- NCT07084363 — Quantitative Versus qUAlitative NeuromoniToring of neUroMuscular Block for Non-cardiothoracic Surgery · NA · recruiting
- NCT06945341 — International Focus Group Discussion on Neuromuscular Monitoring. · recruiting
Other Seoul National University Hospital trials
Trials by the same sponsor.
- NCT07262944 — EOI Block in Otoplasty With Rib Cartilage Graft · NA · recruiting
- NCT07464210 — Nemtabrutinib, Bortezomib, and Rituximab for WM · Phase 2 · not yet recruiting
- NCT07550803 — Effect of Intraoperative Dexamethasone on Early Postoperative Sleep Quality in Patients Undergoing Nasal Surgery · NA · not yet recruiting
- NCT07522138 — Home-based Self-exercise in Patients With Parkinson's Disease: A Feasibility Study · NA · not yet recruiting
- NCT07476651 — Scout Dose of Resin Microspheres · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05724550 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Seoul National University Hospital
- Last refreshed: 8 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05724550.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing